Form 4: Supernus Pharmaceuticals Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, executed stock options and sold shares according to a pre-arranged trading plan.

Summary

• On March 19, 2024, Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, exercised options to acquire 12,364 shares of common stock at a price of $25.30 per share.
• On the same day, Bhatt sold 12,364 shares of common stock at a weighted average price of $35.31, with individual sales ranging from $35.30 to $35.34.
• These transactions were executed under a 10b5-1 trading plan adopted on September 7, 2023.
• Following these transactions, Bhatt directly owns 8,570 shares of Supernus common stock and 27,636 derivative securities (employee stock options).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it's simply a report of activity.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of 10b5-1 plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates